CAR T treatment for CD30-positive lymphomas after standard therapies
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a lab-made immune cell therapy (CAR T) that targets CD30 on certain lymphoma cells. It may help people whose Hodgkin or non-Hodgkin lymphoma has come back or did not respond to usual treatments, including transplant and other medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CD30-positive Hodgkin or non-Hodgkin lymphoma that is back after transplant or hard to treat
- You may need this trial because you can’t get or finish standard chemotherapy
- Your overall strength/ability to do daily activities is good (Karnofsky or Lansky score over 60)
- Your kidneys and liver blood tests are in acceptable ranges
- Your lungs work well enough on breathing tests and your oxygen stays above 90% on room air
- Your own immune cells can be collected, and at least 10% have the needed CD30-based feature
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
This trial tests a new treatment called LCAR-HL30 for people with Hodgkin's lymphoma or anaplastic large cell lymphoma that has come back or not responded to therapy. The treatment targets cells with a protein called CD30 to help your body fight the cancer.
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
This trial tests a new treatment called CD30 CAR-T, which uses your own immune cells to attack lymphoma cells that have the CD30 protein. It is for people whose lymphoma has come back or not responded to at least 2 prior treatments.
This trial tests a new type of immunotherapy called CD30 CAR-T cells for people with CD30-positive lymphoma that has come back or hasn't responded to other treatments. The treatment uses your own immune cells that are specially trained to find and kill lymphoma cells carrying the CD30 marker.
This trial tests a new treatment using your own immune cells (T-cells) that are specially designed to attack a protein called CD30 found on Hodgkin lymphoma cells. It's given after a stem cell transplant to try to prevent the cancer from coming back in people with high-risk disease.
Hear when a new Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.